Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT05989763
- Status
- Recruiting
Conditions
- Autonomic Dysfunction
- Constipation
- Gastrointestinal Motility Disorder
- Systemic Sclerosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Transcutaneous Electrical Acustimulation (TEA) — DEVICETEA will then be administrated for 1 hour twice daily for a period of 4 weeks
- Sham-TEA — DEVICESham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
Study Details
The purpose of this study is to determine whether transcutaneous electrical acustimulation (TEA) alters systemic sclerosis (SSc)-related colonic and anorectal physiology by enhancing autonomic nervous system (ANS) function. The study will examine the effects of TEA on slow colonic transit (SCT) and rectal hyposensitivity (RH), to examine whether TEA improves autonomic dysfunction and modulates inflammatory pathways.
Key Dates
- Start date
- Feb 17, 2024
- Status verified
- Jun 2025
- Primary completion
- Aug 14, 2028
- Completion
- Sep 1, 2029
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Transcutaneous Electrical Acustimulation (TEA)
- Sham Comparator: Sham-TEA
Primary Outcome Measure
Change in slow colonic transit (SCT) [ Time Frame: baseline, week 4 (visit 2) ]
Central Contacts
- Zsuzsanna H McMahan, MD, MHS (M-PI)7135007531
- Sharvari R Kamat713-500-6898
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 |
Find similar trials in Houston, TX
Related Studies
- VNS Prospective Neuromodulation of Immune and Gastrointestinal SystemsRecruiting · University of Louisville · Louisville, Kentucky
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Aurora, Colorado
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)PHASE1/PHASE2 · Recruiting · Nkarta, Inc. · Orange, California